🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · Canada

Clinical Trials in London, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Toronto 2809 Montreal 1902 Vancouver 1179 Calgary 1061 Edmonton 1017
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's108 Western University, Canada39 AstraZeneca36 Novartis Pharmaceuticals24 Eli Lilly and Company23
Site location
Toronto2809 Montreal1902 Vancouver1179 Calgary1061 Edmonton1017
All 255 locations
Target enrolment
to

Trials with a site in London

871 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Calgary, Winnipeg, London, Chicoutimi, Montr Al, Rimouski
2027-11-23
Not yet open
WSO BEAT STROKE Initiative
NCT06606054Stroke, PFO - Patent Foramen Ovale, Atrial Fibrillation (AF)
Luciano A. Sposato
Not applicable
2,400
London
2027-03
Not yet open
Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults
NCT07706361GHK and GHK-Cu Blood Levels
LifeWave, Inc.
Not applicable
100
London
2027-01
Not yet open
Brain-based Prediction of the Dying Duration in Humans After Withdrawal of Life Sustaining Therapies to Inform Donation After Circulatory Death
NCT07698262Organ Donation After Circulatory Death
University of British Columbia
Observational
102
Calgary, Cranbrook, Kelowna, New Westminster, Surrey, Vancouver, Winnipeg, London
2027-01
Not yet open
Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer
NCT07510906Prostate Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
25
London
2026-12-30
Not yet open
Sustained Asthma Remission and Reduced Relapse Using a Comprehensive Management Strategy (SARRE-COMS)
NCT07816718Asthma (Diagnosis)
Hana Serajeddini
Not applicable
50
London
2026-12-02
Not yet open
A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis
NCT07654517Idiopathic Subglottic Stenosis, Subglottic Stenosis (SGS)
DrugPirfenidone
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1
40
London
2026-12-01
Not yet open
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
NCT07281027New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
DrugsAnakinra·Tocilizumab
Yale University
Phase 3
438
London, Toronto
2026-12-01
Not yet open
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
NCT07831122Relapsed Refractory Multiple Myeloma (RRMM)
DrugsCevostamab·Belantamab mafodotin·Pomalidomide
Canadian Myeloma Research Group
Phase 1
108
Edmonton, Halifax, London, Ottawa, Toronto, Montreal
2026-12
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Victoria, London, Montreal
2026-11-30
Not yet open
Mechanistic 129 Xe MRI Study to Assess Therapeutic Response in Fibrotic Interstitial Lung Disease
NCT07786090Fibrotic Interstitial Lung Disease
Dr. Grace Parraga
Observational
35
London
2026-11
Not yet open
A Clinical Trial to Investigate the Efficacy of BioCopper1®, Restore Cu1, and Grow + Restore Cu1 on Hair and Skin Improvements in Healthy Adults
NCT07839494Grey Hair, Hair Growth, Skin Health
Mitosynergy LLC
Not applicable
88
London
2026-11
Not yet open
Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury
NCT07588711Spinal Cord Injury, Neuropathic Pain
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
32
London
2026-10-01
Not yet open
Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Musculoskeletal Pain in Cerebral Palsy
NCT07585292Cerebral Palsy (CP), Musculoskeletal Pain
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
32
London
2026-10-01
Not yet open
REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)
NCT07174713Asthma; Eosinophilic
Western University, Canada
Not applicable
200
London
2026-10-01
Not yet open
The BASIC-S Feasibility Study for Vascular Risk Reduction
NCT07755631Hypertension (HTN), Vascular Diseases, Stroke, Dementia
Andrew Appleton
Not applicable
120
London
2026-10-01
Not yet open
The PERK Study: Predicting and Evaluating Response to Knee RFA Using fNIRS
NCT07835269Osteo Arthritis of the Knee, Pain
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
30
London
2026-10
Not yet open
A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control
NCT07711288Postprandial Glycemic Control, Prediabetic Overweight and Obese Adults
Lembas
Not applicable
35
London
2026-10
Not yet open
A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
NCT07288528Cough, Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity Syndrome
DrugPregabalin
McMaster University
Phase 4
124
Calgary, Hamilton, London, Québec, Sherbrooke
2026-09-30
Not yet open
Genistein for the Reduction of Adverse Cardiovascular Events (GRACE)
NCT07785388HIV, Vascular Disease, Inflammation, Pain Management
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1/2
60
London
2026-09-30
Not yet open
An OLIP Study (Open Label Individual Patient) of Nusinersen in a Participant With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen
NCT07838779SMA - Spinal Muscular Atrophy
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
1
London
2026-09-17
Not yet open
Labral Repair vs Reconstruction
NCT07608237Femoral Acetabular Impingement
Western University, Canada
Not applicable
220
London
2026-09-01
Recruiting
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305Renal Insufficiency, Chronic
DrugsBalcinrenone/dapagliflozin·Dapagliflozin
AstraZeneca
Phase 3
2,800
Calgary, Edmonton, Winnipeg, Halifax, Brampton, Greater Sudbury, London, Mississauga
2026-09-01
Not yet open
Trauma Therapy for Weight-Based Bullying in Children
NCT07685990Pediatric Obesity, Weight-based Bullying, Psychological Trauma
Western University
Not applicable
30
London
2026-09-01
Not yet open
Intramedullary Screw Fixation Versus Closed Reduction and Percutaneous Pinning With Cast Immobilization
NCT07616947Metacarpal Fracture, Phalanx Fracture
Spencer B Chambers
Not applicable
100
London
2026-09-01
Not yet open
Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
NCT07485062Type 2 Diabetes, Cognitive Decline in Older Adults
DrugSemaglutide
Western University, Canada
Phase 4
164
London
2026-09-01
Not yet open
Veech Ketone Ester to Support Brain Energy in Mild Cognitive Impairment and Early Alzheimer's Disease
NCT06767124Alzheimer Disease and Related Dementias (ADRD)
University of Pennsylvania
Not applicable
17
London
2026-09-01
Recruiting
Accelerated iTBS for PTSD and Depression
NCT07682207Post Traumatic Stress Disorder PTSD, Major Depressive Disorder (MDD)
Lawson Research Institute of St. Joseph's
Not applicable
16
London
2026-09
Not yet open
MICRO-ultrasound Guided Prostate SBRT
NCT07737457Prostate Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
112
London
2026-09
Recruiting
The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal Transplantation
NCT07726134Delayed Graft Function, Kidney Transplantation
DrugsMannitol·Furosemide
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
160
London
2026-09
Not yet open
A Virtual Clinical Trial to Examine the Effect of Magnesium Choline Citrate on Cognitive Function and Anxiety in Healthy Adolescents and Adults
NCT07685613Cognitive Function, Anxiety
Nutrisol, LLC
Not applicable
200
London
2026-09
Not yet open
Post-osteoporotic Fracture Exercise Program
NCT07595991Osteoporosis, Osteoporotic Fracture
Western University, Canada
Not applicable
100
London
2026-09
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Barrie, Etobicoke, Greater Sudbury, Hamilton, Kingston, London, Markham, Newmarket
2026-08-24
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
7,000
Calgary, Edmonton, Vancouver, Winnipeg, Saint John, London, Scarborough Village, Toronto
2026-08-21
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Calgary, Vancouver, Kingston, London, Toronto, Montreal
2026-08-05
Recruiting
DDAVP Effect by TEG6 in Cardiac Surgery
NCT07179991Intraoperative Bleeding
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
100
London
2026-08-01
Not yet open
A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults
NCT07363148Obese, Overweight Adults, Obese Adults, Body Weight Control
Arrae
Not applicable
120
London
2026-08
Not yet open
A Clinical Trial to Investigate the Efficacy and Safety of a Plant-based Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
NCT07695714Joint Health, Mobility, Knee Pain
Everwell Health
Not applicable
80
London
2026-08
Not yet open
A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults
NCT07692633NAD+ Bioavailability, NAD+ Safety, NAD+ Efficacy
Reus Research
Not applicable
80
London
2026-08
Not yet open
The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults
NCT05664009Fatigue, Cancer, Treatment-Related
Canada Royal Enoch Phytomedicine Co., Ltd.
Not applicable
72
London
2026-08
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Winnipeg, London, North York, Toronto, Vaughan
2026-07-31
Recruiting
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
NCT07681271Papulopustular Rosacea
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
100
London, Markham
2026-07-30
Recruiting
A Post Authorization Registry Study of Participants Treated With LEQEMBI
NCT07762092Alzheimers Disease
Eisai Limited
Observational
400
Calgary, Edmonton, Vancouver, Victoria, Kingston, London, Mississauga, Ottawa
2026-07-30
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Calgary, Edmonton, London, Toronto
2026-07-27
Recruiting
A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems
NCT07388576Cognition, Cognitive Function
Rousselot BVBA
Not applicable
120
London
2026-07-22
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
DrugsRilvegostomig·Enfortumab Vedotin·Datopotamab deruxtecan·Opdivo
AstraZeneca
Phase 3
915
Calgary, Abbotsford British Columbia, Barrie, Hamilton, Kingston, London, Mississauga, Montreal
2026-07-16
Recruiting
A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems
NCT07388043Cognition, Cognitive Performance
Rousselot BVBA
Not applicable
120
London
2026-07-15
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
710
London
2026-07-10
Recruiting
A Clinical Trial to Assess the Pharmacokinetic Profile of Propylene Glycol (PG) in Healthy Adults Following PG Exposure
NCT07644169Healthy, Pharmacokinetic Profile, Propylene Glycol
American Beverage Association
Not applicable
30
London
2026-07-02
Not yet open
¹²⁹Xe(XENON) MRI Program
NCT07533981Healthy Volunteers - Male and Female
Alexei Ouriadov
Not applicable
200
London
2026-07-01
Not yet open
Assessment of a Wearable Ultrafiltration Device
NCT06832696Hemodialysis, Ultrafiltration
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
18
London
2026-07-01
Not yet open
A Clinical Trial to Investigate the Efficacy of Acacia Fiber on Gastrointestinal Health and Microbiota Composition in Healthy Adults With Occasional Constipation
NCT07703254Occasional Constipation, Gastrointestinal Health, Gut Microbiota Composition
Nexira
Not applicable
105
London
2026-07
Not yet open
A Clinical Trial to Investigate the Efficacy and Safety of GenLabs' Social Renew on Improving Acne Symptoms and Skin Repair Among Healthy Adults
NCT07127523Acne
GenCanna Acquisition Corp
Not applicable
150
London
2026-07
Active, closed
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122Obesity, Overweight
DrugBI 3034701
Boehringer Ingelheim
Phase 2
342
Surrey, Victoria, Guelph, Hamilton, London, Stouffville, Toronto, Chicoutimi
2026-06-30
Not yet open
Feasibility of Structured Resistance Training After Lower Extremity Fracture
NCT07629180Lower Extremity Fractures
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
40
London
2026-06-15
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugsCliramitug·Eplontersen
AstraZeneca
Phase 2
326
Calgary, Vancouver, Halifax, London, Toronto, Montreal
2026-06-11
Not yet open
Staph Nasal Decolonization to Improve Function and Feeding
NCT07524894Radiation Mucositis, Staphylococcal Aureus Infection, Head and Neck Cancer
DrugMupirocin
David Palma
Phase 2
126
London
2026-06-01
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Edmonton, Vancouver, London, Toronto, Montreal, Saskatoon
2026-06-01
Not yet open
A Clinical Trial to Investigate the Safety and Efficacy of Bloat on Postprandial Bloating and Its Effects Over Time in Healthy Women
NCT07370740Bloating, Gastrointestinal Symptoms, Intestinal Gas
Arrae
Not applicable
100
London
2026-06
Recruiting
Extended Interval Dosing of Gentamicin in Neonates
NCT07460349Early Onset Sepsis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
42
London
2026-06
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
Edmonton, Vancouver, Kentville, Barrie, Hamilton, London, Toronto, Montreal
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
Edmonton, Vancouver, Kentville, London, Mississauga, Toronto, Montreal
2026-05-22
Not yet open
¹⁹F (Perfluoropropane) MRI
NCT07305532Healthy Volunteers - Male and Female
Alexei Ouriadov
Not applicable
200
London
2026-05-20
Recruiting
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID
NCT07627815Long COVID
ParagonClinicals Inc.
Phase 2
82
Brampton, London, Mississauga, North York
2026-05-20
Recruiting
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07571174Amyotrophic Lateral Sclerosis
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Calgary, London, Montreal, Toronto
2026-05-14
Recruiting
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07571200Amyotrophic Lateral Sclerosis
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Calgary, London, Montreal, Toronto
2026-05-14
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
DrugsPF-08653945·Berobenatide
Pfizer
Phase 2
940
Bridgewater, Brampton, Etobicoke, London, Sarnia, Toronto, Chicoutimi, Mirabel
2026-05-11
Recruiting
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
NCT07573462Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 3
2,400
London, Sarnia
2026-05-04
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Lethbridge, London, Vaughan
2026-05-04
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Lethbridge, London, Vaughan
2026-05-04
Recruiting
A Clinical Trial to Explore the Efficacy of Two Investigational Products on Post-Exercise Hydration in Recreationally Active Healthy Adults
NCT07564661Hydration Status
Chobani
Not applicable
32
London
2026-05-01
Recruiting
129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation
NCT07192016Chronic Obstructive Pulmonary Disease (COPD)
Western University, Canada
Phase 4
60
London
2026-04-24
By invitation
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
NCT07393373Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2
135
London, Ottawa, Montreal
2026-04-23
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
DrugsRisankizumab·Guselkumab
Janssen Research & Development, LLC
Phase 3
530
Edmonton, Vancouver, Hamilton, London, Oshawa, Toronto, Montreal
2026-04-21
Recruiting
Pediatric Evaluation and Registry for Liver Cholestasis in Canada
NCT07411716PFIC - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome (ALGS), Cholestasis, Intrahepatic
Children's Hospital of Eastern Ontario
Observational
220
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, London
2026-04-21
Recruiting
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
NCT06997965Crohn Disease
DrugMirikizumab
Alimentiv Inc.
Phase 4
60
Vancouver, London, Scarborough Village
2026-04-20
Not yet open
Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers
NCT03166072Low Vision, One Eye, Unspecified Eye, Low Vision Blindness
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
150
London
2026-04-20
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
648
Fredericton, Hamilton, London, Québec, Verdun
2026-04-16
Recruiting
Sensory Motor Arousal Regulation Treatment (SMART) Study
NCT06035809PTSD, Post-traumatic Stress Disorder
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
80
London
2026-04-15
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Chicoutimi, London, Ottawa, Richmond Hill, Toronto, Verdun
2026-04-14
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
London, Sault Ste. Marie
2026-04-13
Recruiting
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
NCT07500506Lyme Disease
DrugVLA15
Pfizer
Phase 3
1,712
London, Stouffville, Sherbrooke
2026-04-08
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Greater Sudbury, Halifax, London
2026-03-26
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
DrugApecotrep
Boehringer Ingelheim
Phase 2
132
Calgary, London, Monteral
2026-03-23
Recruiting
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603Lichen Planopilaris
DrugBrepocitinib
Priovant Therapeutics, Inc.
Phase 2/3
342
Edmonton, Guelph, London, Toronto
2026-03-19
Recruiting
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07474792Plaque Psoriasis
DrugORKA-002
Oruka Therapeutics, Inc.
Phase 2
160
Edmonton, Surrey, Barrie, London, North Bay, Peterborough, Toronto, Waterloo
2026-03-19
Recruiting
PRedictors Of Maladaptive Behaviors in Children Undergoing Procedural SEDation
NCT07495826Procedural Sedation and Analgesia
London Health Sciences Centre Research Institute
Observational
2,145
London
2026-03-18
Recruiting
A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients
NCT06474273Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
DrugsMethylprednisolone·Prednisone
University of Sydney
Phase 3
540
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, London, Toronto, Montreal
2026-03-13
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
272
London, Ottawa
2026-03-09
Recruiting
PAXT: Pulmonary Imaging of Mild Asthma Using 129Xe MRI and Tc-99-Labeled-Carbon-Imaging (Tc99CImaging)
NCT07143747Mild Asthma
Dr. Grace Parraga
Observational
40
London
2026-03-02
Recruiting
A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.
NCT06979180CIN - Cervical Intraepithelial Neoplasia, CIN 1, CIN 2, HPV
Papillex Inc.
Not applicable
60
London
2026-03-01
Not yet open
Speech-Evoked Auditory Potentials: Multisite Pediatric Evaluation
NCT07392164Hearing Impairment
Susan Scollie
Not applicable
20
Halifax, London
2026-03
Not yet open
A Clinical Trial to Determine the Safety and Efficacy of an Origin Satiety Complex on Self-reported Hunger and Satiety in Healthy Adults
NCT07390266High BMI, Hunger, Satiety, Healthy Adults
Vora Life LLC
Not applicable
30
London
2026-03
Recruiting
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
NCT07339423Obesity
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
1,150
Calgary, Surrey, Moncton, Halifax, London
2026-02-24
Recruiting
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
240
Edmonton, Surrey, Ajax, London, Markham, Peterborough, Toronto, Waterloo
2026-02-23
Recruiting
Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes
NCT07149064Normoglycemia, Prediabetes, Glycemic Control
Rousselot BVBA
Not applicable
60
London
2026-02-18
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Vancouver, London, Montreal
2026-02-16
Not yet open
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
NCT07348107Advanced Pancreatic Ductal Adenocarcinoma
DrugsATRA·Arsenic Trioxide·Nab-paclitaxel·Tislelizumab
Daniel Breadner
Phase 1
10
London
2026-02-15
Recruiting
Restrictive Fluid Management In Liver Transplantation (REFIL)
NCT07695363Liver Transplantation (LT), End-stage Liver Disease (ESLD)
Centre hospitalier de l'Université de Montréal (CHUM)
Not applicable
866
Vancouver, London, Montreal
2026-02-15
Recruiting
A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes
NCT07195994Prediabetes / Type 2 Diabetes
QuickSilver Scientific
Not applicable
90
London
2026-02-05
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Calgary, Chicoutimi, Edmonton, London, Ottawa, Québec, Vancouver
2026-02-05
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
400
Calgary, Vancouver, Halifax, Hamilton, London, Toronto, Montreal
2026-02-04
Recruiting
Piloting a Brief, Online Intervention for Suicidality in Sexual and Gender Minority Youth
NCT07402265Suicidal Thoughts, Sexual and Gender Minorities, Youth
Western University
Not applicable
250
London
2026-02-01
Not yet open
Feasibility and Usability of a Mobile App for Monitoring and Managing Functional Movement Disorders
NCT07372755Functional Movement Disorder
Western University, Canada
Observational
10
London
2026-02-01
Not yet open
FMT in Triple Negative Breast Cancer Guided by ctDNA
NCT07292142Breast Cancer
DrugFecal Microbiota Transplantation
Jewish General Hospital
Phase 1/2
125
London, Ottawa, Montreal
2026-02
Not yet open
Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial
NCT07300566Prostate Cancer
Joelle Helou
Phase 2
58
London
2026-02
Not yet open
Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders.
NCT07302308Functional Movement Disorder
Western University, Canada
Observational
30
London
2026-01-31
Recruiting
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
NCT07245394Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
DrugsTremfya·Guselkumab
TIDHI Innovation Inc.
Observational
200
Calgary, Fredericton, Hamilton, Barrie, Brampton, London, Mississauga, Oakville
2026-01-29
Recruiting
Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)
NCT07063862Psychological Distress
DrugPsilocybin
Bruyère Health Research Institute.
Phase 3
120
Brampton, Kingston, London, Newmarket, Ottawa, Montreal
2026-01-28
Active, closed
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
600
Brampton, Courtice, Hamilton, Joliette, London, Québec, Sherbrooke, Toronto
2026-01-24
Recruiting
MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)
NCT07244211Femoral Neck Fractures
University of Southern California
Not applicable
600
Vancouver, London
2026-01-23
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184944Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
751
Hamilton, London, New Westminster, Toronto
2026-01-22
Active, closed
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860Dermatitis, Atopic
Janssen Research & Development, LLC
Phase 2
189
Calgary, Ajax, Barrie, London, Mississauga, Niagara Falls, Richmond Hill, Windsor
2026-01-20
Recruiting
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
NCT07188246Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
DrugsKeytruda·Pembrolizumab
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
40
London
2026-01-19
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
DrugsMvasi·Paraplatin·Avastin·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,023
Halifax, London, Toronto, Montreal, Québec, Sherbrooke
2026-01-19
Recruiting
Vorasidenib Maintenance for IDH Mutant Astrocytoma
NCT06809322IDH-mutant Grade 2 or 3 Astrocytoma
DrugVorasidenib
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
468
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, Kingston, London
2026-01-16
Recruiting
The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa
NCT07143981Anorexia Nervosa
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
20
London
2026-01-15
Recruiting
Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
NCT06666348Pediatric Low-grade Glioma
DrugsMirdametinib·Vinblastine
St. Justine's Hospital
Phase 1/2
50
Calgary, Edmonton, Vancouver, Winnipeg, London, Toronto, Montreal, Québec
2026-01-12
Recruiting
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
NCT05723926Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
Javelin Medical
Not applicable
2,000
Hamilton, London
2026-01-09
Recruiting
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
NCT07223697Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
120
London, Markham, Mississauga, Newmarket
2026-01-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Calgary, Edmonton, London, Toronto, Windsor, Chicoutimi, Greenfield Park, Montreal
2026-01-06
Recruiting
Suprazygomatic Maxillary Nerve Block in Pediatric Tonsillectomy
NCT07176533Tonsillitis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
60
London
2026-01-01
Recruiting
Creatine and Resistance Training in Older Adults With Mild Cognitive Impairment
NCT06948149Creatine, Exercise, Mild Cognitive Impairment (MCI)
Western University, Canada
Not applicable
140
London
2026-01-01
Not yet open
The PAPYRUS Study: Permanent vs. Absorbable Sutures in PrimarY Repair of Umbilical HerniaS: A Multicentre, Single-blind, Non-inferiority, Randomized Controlled Trial
NCT07156188Hernia Surgery, Umbilical Hernia Repair
University of British Columbia
Not applicable
914
Edmonton, Barrie, London, North York, Vancouver
2026-01-01
Not yet open
SMART-PD: Evaluating the Impact of Smartphone-Based Wearable Technology on Motor Symptoms and Quality of Life in People With Parkinson's Disease
NCT07066163Parkinson Disease, Idiopathic
Western University
Not applicable
32
London
2026-01
Not yet open
A Clinical Trial to Investigate the Acute Effect of Bragg Apple Cider Vinegar Supplement on Blood Glucose Control in a Healthy Adult Population
NCT07100977Postprandial Glucose, Blood Glucose Concentration
Bragg Live Food Products
Not applicable
24
London
2026-01
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
360
Edmonton, Brampton, London, Toronto
2025-12-22
Recruiting
Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.
NCT07234890Hemodialysis
London Health Sciences Centre Research Institute
Phase 2
60
London
2025-12-16
Recruiting
Real-world Secukinumab Outcomes in Canadian HS Patients
NCT07282015Hidradenitis Suppurativa
Novartis Pharmaceuticals
Observational
142
Calgary, Winnipeg, Fredericton, St. John's, Cobourg, Hamilton, London, Markham
2025-12-12
Recruiting
Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough
NCT06858748Asthma, Chronic Obstructive Pulmonary Disease (COPD), Chronic Cough (CC)
McMaster University
Observational
240
Vancouver, Hamilton, London, Ottawa, Montreal, Québec, Sherbrooke
2025-12-11
Active, closed
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT07228403Short Bowel Syndrome (SBS)
DrugGlepaglutide
Zealand Pharma
Phase 3
28
London
2025-12-11
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Edmonton, Vancouver, Victoria, Halifax, Hamilton, London, Montreal, Québec
2025-12-10
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 3
466
Calgary, Edmonton, London, Toronto, Montreal
2025-12-09
Recruiting
A Clinical Trial to Examine Lysoveta on Cognitive Function in Healthy Adults With Self-perceived Memory Problems
NCT07034794Healthy, Memory Problems
Aker BioMarine Human Ingredients AS
Not applicable
138
London
2025-12-06
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Edmonton, Winnipeg, St. John's, London, Richmond Hill, Toronto, Montreal
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Hamilton, London, Toronto, Whitby
2025-12-02
Not yet open
A Cognitive Behavioral Therapy Approach to Addressing Anxiety in Children With ASD and Intellectual Disability
NCT07245160Autism Spectrum Disorder (ASD), Intellectual Disability
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
24
London
2025-12-01
Recruiting
Manual T-piece Versus Ventilator Positive Pressure Ventilation During Resuscitation of Extremely Premature Neonates
NCT06849596Neonatal Resuscitation, Apnea Neonatal
Michelle Baczynski
Not applicable
780
Calgary, Edmonton, Vancouver, Hamilton, London, Toronto, Montral, Montreal
2025-12-01
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 3
468
London, Montreal, Toronto
2025-11-25
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Edmonton, Vancouver, London, Toronto, Montreal, Saskatoon
2025-11-19
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Hamilton, London, Whitby, Montreal, Québec
2025-11-19
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
320
Barrie, Calgary, Fredericton, London, Québec, Red Deer, Surrey
2025-11-14
Recruiting
Oral Carnitine in Heart Failure Patients
NCT07201714Heart Failure, Carnitine Deficiency
DrugLevocarnitine
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase EARLY_PHASE1
20
London
2025-11-12
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Kelowna, Halifax, London, Ottawa, Peterborough, Toronto, Montreal
2025-11-12
Active, closed
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
NCT07216482Hyperlipidemia
DrugsEnlicitide·Enlicitide Decanoate·Rosuvastatin
Merck Sharp & Dohme LLC
Phase 3
996
Moncton, London, North York, Thunder Bay, Mirabel, Québec
2025-11-11
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Edmonton, Vancouver, London, Ottawa, Toronto
2025-11-10
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Hamilton, London, Mississauga, Trois-Rivières
2025-11-10
Recruiting
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
NCT07027436Hepatocellular Carcinoma (HCC)
Hamilton Health Sciences Corporation
Phase 3
30
Hamilton, London
2025-11-07
Recruiting
Effects of Bacillus Coagulans SNZ 1969 on Immune Health in Healthy School-aged Children
NCT07341750Immunity
Sanzyme Biologics Private Limited
Not applicable
100
London
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759Overweight, Obesity, Type 2 Diabetes
DrugCagrilintide
Novo Nordisk A/S
Phase 3
330
Kelowna, Moncton, Halifax, Brampton, Hamilton, London, Pointe-Claire, Victoriaville
2025-11-05
Active, closed
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642Obesity, Overweight
DrugCagrilintide
Novo Nordisk A/S
Phase 3
300
Moncton, Halifax, Hamilton, London, Oshawa, Toronto, Mirabel
2025-11-05
Not yet open
Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Patients: A Randomized Controlled Trial and Observational Study
NCT07204301Bladder Cancer
Western University, Canada
Not applicable
378
London
2025-11-01
Not yet open
Imaging and Treatment Planning for Cardiac Radioablation
NCT06938074Ventricular Tachycardia, Monomorphic, Ventricular Tachycardia (V-Tach), Ischemia, Myocardial
Stewart Gaede
Not applicable
15
London
2025-11-01
Recruiting
A Study With CIT-013 in HS Patients
NCT06993233Hidradenitis Suppurativa (HS)
DrugsCIT-013 medium·CIT-013
Citryll BV
Phase 2
96
Barrie, Calgary, London, Newmarket, Winnipeg
2025-10-31
Recruiting
A Clinical Trial to Investigate the Effect of Pollen Extracts on Menopausal Symptoms in Healthy Women.
NCT06889753Menopausal Women
Graminex LLC
Phase 2
120
London
2025-10-29
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
London, Toronto, Boisbriand
2025-10-28
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Calgary, Vancouver, Halifax, Hamilton, London, Newmarket, Toronto, Montreal
2025-10-28
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
AtriCure, Inc.
Not applicable
960
Hamilton, London, Montreal
2025-10-24
Recruiting
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
NCT06880523Hepatocellular Carcinoma
DrugsSTRIDE (durvalumab·Tremelimumab·Lenvatinib·Durvalumab
Canadian Cancer Trials Group
Phase 2
140
Calgary, Kelowna, Vancouver, Hamilton, Kingston, Kitchener, London, Mississauga
2025-10-21
Recruiting
Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma
NCT07337161Cutaneous, Head and Neck Cancer Squamous Cell Carcinoma
David Palma
Not applicable
90
London
2025-10-21
Recruiting
B2AD-Risk AFDAS Evolution of Burden of AF
NCT06589700Stroke, Atrial Fibrillation
Luciano A. Sposato
Not applicable
24
London
2025-10-16
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Calgary, Chicoutimi, Edmonton, Halifax, London, North Bay, Québec, Toronto
2025-10-15
By invitation
Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors
NCT07100054CDK4/6 Inhibitor, Breast Cancer, CYP3A4 Protein, Human, Drug Interaction
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
100
London
2025-10-10
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
Observational
223
Calgary, London, Ottawa, Sherbrooke
2025-10-08
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Edmonton, Vancouver, Kentville, Barrie, London, Oakville, Toronto, Montreal
2025-10-03
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628Acute Coronary Syndrome
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
300
Edmonton, Hamilton, London, Newmarket, Montreal, Québec
2025-10-03
Not yet open
Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy
NCT07076914Primary Lung Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
58
London
2025-10-02
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 3
1,280
Calgary, Vancouver, Québec, Halifax, Greater Sudbury, Hamilton, London, Mississauga
2025-10-02
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Edmonton, Vancouver, Kentville, Barrie, London, Mississauga, Oakville, Toronto
2025-10-01
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NCT06745908NSCLC Stage IV
DrugsAnktiva·Tislelizumab·Docetaxel
ImmunityBio, Inc.
Phase 3
507
North Vancouver, Saint John, Brampton, Kitchener, London, Newmarket, Windsor
2025-10-01
Recruiting
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
NCT07175038Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
AllRock Bio, Inc.
Phase 2
40
Calgary, London
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Oakville, Brampton, Edmonton, Greater Sudbury, Hamilton, London, Montreal, New Westminster
2025-10-01
Recruiting
Study of COYA 302 for the Treatment of ALS
NCT07161999Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics
Phase 2/3
120
Vancouver, London, Toronto, Montreal
2025-10-01
Not yet open
The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients
NCT07177157Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
Terry Ponich
Phase 1
150
London
2025-10
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
London, Montreal
2025-09-29
Recruiting
Weight-Bearing CT Periprosthetic Distal Knee Fractures
NCT06525610Periprosthetic Fracture Around Prosthetic Joint Implant Knee
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
21
London
2025-09-24
Recruiting
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
NCT06942039CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor, Medulloblastoma, Childhood
DrugsCytarabine IT·Mesna·Filgrastim·Hydrocortisone
C17 Council
Phase EARLY_PHASE1
15
Calgary, Vancouver, Winnipeg, Halifax, Hamilton, London, Montreal, Québec
2025-09-23
Active, closed
Exercise Intensity
NCT07119593Dialysis, Cardioprotection
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
15
London
2025-09-22
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
DrugDupilumab
Sanofi
Phase 4
218
London
2025-09-22
Recruiting
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
NCT07094087Complex Cardiovascular Surgery With Cardiopulmonary Bypass
CSL Behring
Phase 3
200
Kingston, London, Toronto, Montreal
2025-09-15
Recruiting
Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes
NCT06840756Red Blood Cell Transfusions, Sex Differences, Health Services, Critically Ill Intensive Care Unit Patients
Michelle Zeller
Phase 4
11,082
Hamilton, Kingston, London, Oshawa, Ottawa, Toronto
2025-09-11
Recruiting
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT07039110Plaque Psoriasis
AbbVie
Observational
700
Calgary, Edmonton, Winnipeg, Ajax, Belleville, Hamilton, London, Markham
2025-09-09
Recruiting
An Evaluation of Dose-escalation for Intrathoracic Tumours
NCT06794125Lung Cancers
Chris Goodman
Not applicable
141
Kelowna, Saint John, London, Waterloo
2025-09-03
Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
NCT07136467Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
AbbVie
Observational
2,795
Calgary, Edmonton, Fredericton, Barrie, London, Markham, Richmond Hill, Pointe-Claire
2025-09-02
Not yet open
Intermittent Fasting for Inflammation and Depression in Spinal Cord Injury
NCT06807528Spinal Cord Injury, Depression - Major Depressive Disorder
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
32
London
2025-09-01
Recruiting
Single vs. Dual Implant Fixation for Distal Femur Fractures in Older or Compromised Adults
NCT06944964Distal Femur Fractures
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
44
New Westminster, London
2025-09-01
Not yet open
Study of Sensory Attenuation in Functional Movement Disorders
NCT06872788Functional Movement Disorder
Western University, Canada
Observational
70
London
2025-09
Not yet open
Testing of a New Joint Protection Program
NCT06963164Hand Osteoarthritis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
60
London
2025-09
Recruiting
Gut Microbiome in Orthopaedics: Revision Total Knee Arthroplasty
NCT06951477Revision Total Knee Arthroplasty, Osteoarthritis, Knee
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
30
London
2025-08-21
Recruiting
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192Psychosis Associated With Alzheimer's Disease
DrugML-007C-MA
MapLight Therapeutics
Phase 2
300
Brampton, London, Toronto, Lévis
2025-08-15
Recruiting
DIALysis With EXpanded Solute Removal
NCT06660277Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD), Chronic Kidney Disease Requiring Chronic Dialysis, Pragmatic Randomized Controlled Trial
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
4,800
London, Orillia, Ottawa
2025-08-12
Active, closed
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199Diabetes Mellitus, Type 1
DrugsInsulin aspart·Insulin glargine·Insulin icodec
Novo Nordisk A/S
Phase 3
877
Calgary, Vancouver, Winnipeg, Halifax, Brampton, Etobicoke, Hamilton, London
2025-08-11
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
DrugVHB937
Novartis Pharmaceuticals
Phase 2
407
London, North York, Ottawa, Toronto
2025-08-07
Active, closed
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
NCT07092865Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 2
168
Edmonton, Vancouver, London, Toronto
2025-08-06
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Calgary, Abbotsford British Columbia, Vancouver, Barrie, Brampton, London, Toronto, Chicoutimi
2025-08-06
Recruiting
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07100119ALS (Amyotrophic Lateral Sclerosis)
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Calgary, Edmonton, London, Montreal, Toronto
2025-08-05
Not yet open
Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study
NCT07073729Neurotrophic Keratitis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
10
London
2025-08-01
Recruiting
Cryoneurolysis for Spasticity Treatment: Long-term Clinical Outcomes and Mechanisms in the Central Nervous System
NCT06958289Spasticity as Sequela of Stroke
Sue Peters
Not applicable
25
London
2025-08-01
Recruiting
Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
NCT05749094Giant Cell Arteritis, Anterior Ischemic Optic Neuropathy, Optic Neuropathy, Ischemic
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Observational
285
London, Toronto, Montreal, Sherbrooke
2025-08
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
DrugRisankizumab
AbbVie
Phase 3
120
Calgary, Edmonton, London
2025-07-28
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
London, Ottawa, Toronto
2025-07-21
Active, closed
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330Plaque Psoriasis
DrugORKA-001
Oruka Therapeutics, Inc.
Phase 2
80
Edmonton, Surrey, Hamilton, London, Markham, Peterborough, Toronto, Waterloo
2025-07-18
Recruiting
A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
NCT06932458Testicular Cancer
Western University, Canada
Phase 2
30
London
2025-07-17
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Adrucil·Cetuximab
Merck Sharp & Dohme LLC
Phase 3
477
Winnipeg, Moncton, London, Toronto, Chicoutimi, Montreal
2025-07-16
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
DrugMezagitamab
Takeda
Phase 3
347
Calgary, London, Toronto
2025-07-15
Recruiting
Feasibility Trial for a Right Ventricular Failure Platform Trial
NCT06570473Pulmonary Hypertension, Right Ventricular Dysfunction, Right Heart Failure
DrugsRanolazine·Dapagliflozin
University of Alberta
Phase 2
30
Calgary, Edmonton, Vancouver, London, Ottawa
2025-07-15
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Hamilton, London, Toronto, Whitby, Montreal
2025-07-10
Recruiting
Ablative Radioembolization of Renal Cell Carcinoma Trial
NCT06642220Renal Cell Carcinoma (RCC), Radioembolization
Derek W. Cool
Phase 2
16
London
2025-07-09
Recruiting
A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women
NCT07022925Perimenopause, Perimenopausal Depression, Perimenopausal Insomnia, Perimenopausal Women
IdentifyHer Limited
Observational
110
London
2025-07-04
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
Calgary, London, Toronto, Vancouver
2025-07-02
Recruiting
Akkermansia Muciniphilia and Metabolic Side Effects of ADT
NCT05802121Prostate Cancer, Metabolic Syndrome, Obesity, Cardiovascular Morbidity
Western University
Phase EARLY_PHASE1
30
London
2025-07-02
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352Alzheimers Disease
Hoffmann-La Roche
Phase 3
80,000
Kelowna, Richmond, Halifax, London, Ottawa, Peterborough, Toronto, Montreal
2025-07-02
Not yet open
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
NCT04986605Diffuse Cutaneous Systemic Sclerosis
DrugUvadex
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
15
London
2025-07-01
Not yet open
Optimal Nutritional Palliation of Obstructed GEJ Cancer
NCT06876454Esophageal Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
33
London
2025-07-01
Recruiting
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
NCT07028749Hypertriglyceridemia
DrugMAR001
Marea Therapeutics
Phase 2
316
Concord, London, Sarnia, Chicoutimi, Montreal, Québec
2025-06-30
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07007637Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
835
Calgary, Edmonton, Sherwood Park, Winnipeg, Fredericton, Barrie, Guelph, London
2025-06-27
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
350
London, Montreal, Ottawa, Vancouver
2025-06-26
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099Crohn's Disease, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
290
Edmonton, London, Montreal, Ottawa, Vancouver
2025-06-26
Active, closed
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
NCT07225829Knee Osteoarthritis, Synovitis of Knee
4Moving Biotech
Phase 2
129
Ajax, London, Québec
2025-06-17
Recruiting
The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers
NCT06937814GI Issues, Bowel Movements, Gastrointestinal Symptoms
dsm-firmenich Switzerland AG
Not applicable
250
London
2025-06-16
Recruiting
Optimizing Recruitment to Drive Equitable Research Opportunity in Stroke Rehabilitation Trials in Canada
NCT06576089Stroke
McMaster University
Not applicable
120
Calgary, Vancouver, Halifax, London, Toronto
2025-06-16
Active, closed
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792Atopic Dermatitis
DrugLebrikizumab
Eli Lilly and Company
Phase 4
233
Fredericton, Halifax, London, Nanaimo, Ottawa, Peterborough, Sherbrooke, Thunder Bay
2025-06-16
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
573
Edmonton, Winnipeg, Fredericton, Hamilton, London, Markham, Mississauga, Saskatoon
2025-06-12
Recruiting
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
NCT06914609Angelman Syndrome
DrugObudanersen
Ionis Pharmaceuticals, Inc.
Phase 3
158
London, Montreal, Edmonton, Vancouver
2025-06-10
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Vancouver, London, Chicoutimi, Montreal, Québec, Trois-Rivières
2025-06-10
Recruiting
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
NCT06337838Chronic Kidney Diseases, Acute Kidney Injury, Bleeding, Surgery
DrugsDdavp·Desmopressin
Hamilton Health Sciences Corporation
Phase 3
100
London, Montreal
2025-06-09
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490Multiple Sclerosis Spasticity
DrugIrafamdastat
Celgene
Phase 2
200
Edmonton, London, Ottawa, Toronto, Lévis, Montreal
2025-06-05
Active, closed
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
NCT07027527Atopic Dermatitis
DrugsAPG777·Dupilumab
Apogee Therapeutics, Inc.
Phase 1
86
London, Peterborough, Richmond Hill, Toronto, Montreal, Québec, Sherbrooke
2025-06-04
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Calgary, Vancouver, Winnipeg, Halifax, Hamilton, London, Toronto, Montreal
2025-06-04
Recruiting
Therapeutic Relevance of Abnormal Airway Morphology in Asthma
NCT06970080Asthma
DrugPrednisone
McMaster University
Phase 4
242
Hamilton, London
2025-06-02
Recruiting
Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners
NCT06877598Prostate Cancer, Sexual Dysfunction, Physiological, Sexual Dysfunction, Psychological, Sexual Dysfunction
University Health Network, Toronto
Observational
575
Vancouver, Winnipeg, Barrie, Edmonton, Kingston, London, Mississauga, Ottawa
2025-06-01
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Edmonton, London, Toronto, Montreal
2025-05-30
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
London, Toronto, Greater Sudbury
2025-05-27
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,123
Surrey, Winnipeg, St. John's, Barrie, London, Sault Ste. Marie, Toronto, Windsor
2025-05-22
Recruiting
The Efficacy of a Smart Phone-based Test on Measuring Pupillary Light Reflex Alterations Following Cannabis Use Healthy in Adults
NCT06967051Cannabis Intoxication, Drug Effects
DrugTetrahydrocannabinol
Sobereye Inc.
Not applicable
20
London
2025-05-22
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
DrugsFelzartamab·Tacrolimus
Biogen
Phase 3
180
Vancouver, London
2025-05-22
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 3
150
Hamilton, London, Ottawa, Montreal, Québec, Sherbrooke
2025-05-15
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
425
Barrie, Brampton, London, North YORK, Montreal
2025-05-12
Recruiting
The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
NCT06850766IDH-Wildtype Glioblastoma, Glioblastoma (GBM)
Ottawa Hospital Research Institute
Not applicable
50
London, Ottawa
2025-05-08
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Edmonton, Vancouver, Halifax, London, Toronto
2025-05-06
Recruiting
Caregiver Training to Support Children With Social Communication Challenges
NCT06909279Autism Spectrum Disorder, Suspected Autism, Social Communication Challenges
Western University, Canada
Not applicable
72
London
2025-05-06
Recruiting
Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation
NCT06288152Renal Transplant, Kidney Transplant
DrugSodium Thiosulfate
Alp Sener
Not applicable
120
London
2025-05-03
Recruiting
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
NCT06256575Scleroderma, Systemic, Digital Ulcer
Primus Pharmaceuticals
Not applicable
45
Calgary, Halifax, London, Ottawa, Toronto
2025-05-02
Recruiting
Survivorship After HNC: A Randomized Controlled Trial Evaluating Patient Care and Adherence to Follow-up
NCT06127784Head and Neck Cancer, Survivorship
Western University, Canada
Not applicable
176
London
2025-05-01
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Panitumumab·Leucovorin·Fluorouracil
AbbVie
Phase 2
390
Calgary, Edmonton, London, Toronto, Montreal
2025-04-24
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
DrugPumitamig
BioNTech SE
Phase 1/2
380
Chicoutimi, London, Toronto, Vancouver
2025-04-23
By invitation
An Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT06873035Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2/3
24
London, Ottawa, Montreal
2025-04-22
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
DrugsDactinomycin·Vincrystine·Vincristine·Doxorubicin
Children's Oncology Group
Phase 3
1,656
Calgary, Edmonton, Winnipeg, Halifax, Hamilton, London, Ottawa, Toronto
2025-04-15
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
St. John's, Ajax, Barrie, Hamilton, London, Markham, Waterloo, Montreal
2025-04-15
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Hamilton, London, Ottawa, Greenfield Park, Montreal, SaintJerome
2025-04-10
Active, closed
Novel Approach to Conduction System Pacing With Use of Ultrasound
NCT06815783Conduction Block, Atrioventricular, Bundle-Branch Block
Habib Khan
Not applicable
152
London
2025-04-10
Recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
869
Victoria, Halifax, London, Sarnia, Toronto, Waterloo, Chicoutimi, Montreal
2025-04-09
Recruiting
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
NCT06623461Melanoma
Canadian Cancer Trials Group
Phase 2
128
Abbotsford British Columbia, Surrey, Vancouver, Hamilton, London, Newmarket, Ottawa, Toronto
2025-04-07
Recruiting
Feasibility of a Diet Intervention for Juvenile Arthritis
NCT06474546Arthritis, Juvenile, Arthritis, Childhood, Juvenile Idiopathic Arthritis
The Hospital for Sick Children
Not applicable
54
Winnipeg, Hamilton, London, Ottawa, Toronto, Montreal, Saskatoon
2025-04-07
Recruiting
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165ALS
Amylyx Pharmaceuticals Inc.
Phase 1
48
Calgary, Hamilton, London, Montreal
2025-04-07
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
162
Calgary, London, Markham, Mississauga, Newmarket, Québec
2025-04-01
Recruiting
Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial
NCT06156176Long-COVID, Long COVID-19, Post-COVID-19 Syndrome, Post-COVID Syndrome
Lawson Research Institute of St. Joseph's
Not applicable
60
London
2025-04-01
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Maastricht University
Not applicable
358
Calgary, Vancouver, Halifax, Hamilton, Kingston, London, Toronto, Sherbrooke
2025-04-01
Not yet open
Lipiodal Injection Technique for Free Flap Sparing Adjuvant RT Planning in HNC
NCT06806189Head and Neck Cancer
Western University, Canada
Phase EARLY_PHASE1
10
London
2025-04-01
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 3
674
Calgary, Red Deer, Winnipeg, Barrie, Guelph, London, Markham, Newmarket
2025-04-01
Not yet open
Cognitive Cueing and Video Intervention for Gait in Parkinson's Disease
NCT06894030Parkinson's Disease
Western University, Canada
Not applicable
30
London
2025-04
Recruiting
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06421675Refractory Multiple Myeloma
DrugElranatamab
Ontario Clinical Oncology Group (OCOG)
Phase 2
40
Vancouver, Hamilton, Kingston, London, Ottawa
2025-03-28
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Calgary, Edmonton, Winnipeg, Halifax, London, Toronto, Montreal, Québec
2025-03-27
Recruiting
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
NCT06174220Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
DrugTideglusib
Hamilton Health Sciences Corporation
Phase 2
120
Calgary, Vancouver, Victoria, St. John's, Halifax, Hamilton, Kingston, London
2025-03-21
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
565
Edmonton, London, Montreal, Québec, Sherbrooke
2025-03-20
Active, closed
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
DrugMaridebart cafraglutide
Amgen
Phase 3
1,105
Surrey, Winnipeg, Halifax, Brampton, Concord, Hamilton, London, Nepean
2025-03-17
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Phase 4
274
London, Ottawa, Toronto, Québec
2025-03-14
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Calgary, Edmonton, Vancouver, London, Toronto
2025-03-07
Recruiting
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
NCT06391242Cancer Metastatic
Canadian Cancer Trials Group
Phase 3
230
Calgary, Vancouver, Hamilton, Kingston, London, Newmarket, Toronto, Montreal
2025-03-07
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Edmonton, Surrey, Vancouver, Winnipeg, Saint John, Halifax, Etobicoke, London
2025-03-03
Not yet open
Genomic First Testing in Chronic Kidney Disease
NCT06794567Chronic Kidney Disease(CKD), Genetic Kidney Disease
Dervla Connaughton
Observational
2,400
London
2025-03-01
Not yet open
Passive Thoughts in Functional Movement Disorders
NCT06439017Functional Movement Disorder
Western University, Canada
Observational
60
London
2025-03
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
600
Calgary, Edmonton, Sherwood Park, Vancouver, Winnipeg, Barrie, Cobourg, London
2025-02-28
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Edmonton, Etobicoke, London, Montreal
2025-02-27
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268Sickle Cell Disease
DrugEtavopivat
Novo Nordisk A/S
Phase 3
510
Calgary, Edmonton, Vancouver, London, Scarborough Village, Toronto, Montreal
2025-02-17
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505Chronic Migraine
DrugAtogepant
AbbVie
Phase 3
420
London, Montreal
2025-02-13
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
231
London, Montreal, Québec
2025-02-12
Active, closed
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053Asthma
DrugGSK5784283
GlaxoSmithKline
Phase 2
307
Kelowna, Ajax, London, Toronto, Windsor, Trois-Rivières
2025-02-10
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Edmonton, London, Ottawa, Québec
2025-02-07
Recruiting
Tech-wise Driver (Technology Acceptance of Targeted ADAS for Older Adults)
NCT06437665Older Adults, Driving, Simulator
Western University, Canada
Not applicable
68
London
2025-02-01
Not yet open
EVAluation of Erythrocytosis PRospEctive Cohort STudy
NCT06785870Erythrocytosis, Polycythemia, Polycythemia Secondary, Polycythemia Vera
Cyrus Hsia
Observational
1,500
London
2025-02-01
Active, closed
Love Group for Geriatric Psychiatry Outpatients
NCT06424483Loneliness
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
50
London
2025-02-01
Recruiting
Biobeat Digital Home Monitoring Feasibility
NCT06417996Thoracic Surgery, Home Monitoring
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
48
London
2025-02-01
Recruiting
Exercise Preconditioning to Protect Against Dialysis-induced Cardiac Injury
NCT06735378Hemodialysis, Cardioprotection
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
30
London
2025-01-20
Recruiting
CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)
NCT06393400Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
DrugsFecal Microbiota Transplantation·Nab-paclitaxel·Gemcitabine
John Lenehan
Phase 1
20
London
2025-01-08
Recruiting
Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease
NCT05986318Lung Cancer, Interstitial Lung Disease
DrugDexamethasone
David Palma
Phase 2
98
Vancouver, Saint John, London, Montreal
2025-01-07
Recruiting
Adult Bladder and Quality of Life Evaluation in Spina Bifida
NCT07642466Spina Bifida or Spinal Dysraphism
Blayne Welk
Observational
300
London
2025-01-01
Not yet open
Surgery and Reducing Ionizing Radiation of the Unknown Primary
NCT06578871Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
90
London
2025-01-01
Not yet open
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia
NCT04405596Lewy Body Disease
DrugAmbroxol
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1/2
15
London
2025-01
Not yet open
Handwriting Analysis in Movement Disorders.
NCT06436287Movement Disorders
Western University, Canada
Observational
100
London
2025-01
Recruiting
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
NCT06439225Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
DrugsDocetaxel·Carboplatin
Canadian Cancer Trials Group
Phase 3
236
Calgary, Edmonton, Vancouver, Brampton, Kitchener, London, Ottawa, Toronto
2024-12-30
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
Edmonton, Brampton, London, Toronto, Montreal
2024-12-26
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Edmonton, Kelowna, Surrey, Vancouver, Victoria, Winnipeg, Kingston, London
2024-12-19
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
DrugsBrivekimig·Frexalimab·Rilzabrutinib
Sanofi
Phase 2
84
London, Montreal, Québec, Toronto
2024-12-19
Active, closed
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190Multifocal Motor Neuropathy (MMN), MMN
DrugsEmpasiprubart·Immunoglobulin·IVIG
argenx
Phase 3
154
Gatineau, London, Vancouver
2024-12-18
Recruiting
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
NCT05272826Multiple Myeloma
DrugsIberdomide·Velcade·Isatuximab·Bortezomib
Canadian Myeloma Research Group
Phase 2
75
Edmonton, St. John's, Halifax, London, Toronto, Montreal
2024-12-12
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Barrie, Brampton, London, Toronto, Montreal
2024-12-11
Active, closed
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234Kidney Disease
GlaxoSmithKline
Phase 1
86
London, Toronto, Montreal
2024-12-11
Recruiting
Belimumab in Autoimmune Hepatitis
NCT06381453Autoimmune Hepatitis
DrugBelimumab
University Health Network, Toronto
Phase 2
48
Calgary, Vancouver, Hamilton, London, Toronto
2024-12-11
Not yet open
Venous Excess Ultrasound for Personalized Resuscitation in Septic Shock
NCT06696391Septic Shock, Sepsis, Shock, Critical Care, Intensive Care
Western University, Canada
Phase 3
80
London
2024-12-01
Recruiting
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
NCT06725121Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery, Downstaging
DrugsAtezolizumab & Bevacizumab·Avastin·Tecentriq
University Health Network, Toronto
Phase 1/2
48
London, Toronto
2024-12
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Calgary, Vancouver, Saint John, Halifax, London, Ottawa, Toronto, Lévis
2024-11-26
Recruiting
Comparing Moderately Ultra Hypofractionated Radiation Treatments for Prostate Cancer
NCT06409910Post-Operative Prostate Cancer
University Health Network, Toronto
Phase 2
204
London, Toronto
2024-11-26
Recruiting
International CRDS Registry
NCT06508164Calcium Release Deficiency Syndrome
Population Health Research Institute
Observational
500
Calgary, Vancouver, Hamilton, London, Ottawa, Montreal, Québec
2024-11-21
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
London, Montreal, Ottawa, Saskatoon, Toronto
2024-11-19
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
DrugRimegepant
Pfizer
Phase 3
200
Edmonton, Red Deer, London
2024-11-15
Recruiting
A Feasibility Randomized Trial Evaluating Early vs Late Stent Removal Following Radical Cystectomy and Ileal Conduit Formation for Bladder Cancer
NCT06595446Bladder Cancer Requiring Cystectomy, Ileal Conduit, Urinary Diversion
Western University, Canada
Not applicable
60
London
2024-11-12
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
367
Vancouver, London, Toronto
2024-11-11
Recruiting
PULSED AF Post-Approval Study
NCT06578104Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
580
London, Toronto, Montreal
2024-11-04
Not yet open
Effectiveness of a PMT Intervention to Reduce Alcohol in Young Adults
NCT06615648Behavior, Drinking, Alcohol Drinking, Colorectal Cancer Control and Prevention, Healthy Volunteers
Western University, Canada
Not applicable
152
London
2024-11-01
By invitation
Long-term Follow up of the Stability 1 Trial
NCT06885372LET, ACL Reconstruction, Osteoarthritis (OA) of the Knee
Western University, Canada
Not applicable
510
Banff, Calgary, New Westminster, Winnipeg, Hamilton, Kingston, London
2024-11-01
Recruiting
Domain-specific Aerobic Exercise Training in Coronary Artery Disease
NCT06143332Coronary Artery Disease
Western University, Canada
Not applicable
105
London
2024-11-01
Recruiting
PENG Block vs. Intraoperative Local Anesthetic Infiltration for Total Hip Arthroplasty
NCT05898581Anesthesia
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
60
London
2024-11-01
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Calgary, London, Toronto
2024-10-29
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma
DrugsParaplatin·Etoposide·Carboplatin
Children's Oncology Group
Phase 2
240
Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, London, Toronto, Montreal
2024-10-22
Recruiting
Patient Reported Outcomes Targeting Early Chest Tube Removal (PROTECTR) Study
NCT06444854Lung Surgery, Chest Tube Removal, Enhanced Recovery After Surgery (ERAS)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
130
London
2024-10-22
Active, closed
Radiographic Migration Analysis of the ATTUNE Cementless CR Fixed-Bearing Total Knee Replacement
NCT06189872Osteo Arthritis Knee
Canadian Radiostereometric Analysis Network
Not applicable
30
Winnipeg, Halifax, London
2024-10-21
Recruiting
Transcranial Direct Current Stimulation and Yoga for Knee Osteoarthritis
NCT06228573Knee Osteoarthritis
McMaster University
Not applicable
68
Hamilton, London, Sherbrooke
2024-10-20
Recruiting
DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery
NCT06519747Atrial Fibrillation, Atrial Flutter
Population Health Research Institute
Observational
750
Hamilton, London, St. Catharines, Sherbrooke
2024-10-15
Recruiting
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
NCT06345079Neuroendocrine Tumors
Australasian Gastro-Intestinal Trials Group
Phase 2
78
Edmonton, Vancouver, London, Ottawa, Toronto, Regina, Saskatoon
2024-10-14
Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168Primary Biliary Cholangitis
Ipsen
Observational
424
Montreal, Calgary, London, Ottawa, Vancouver
2024-10-14
Recruiting
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
NCT06619990Ulcerative Colitis (UC)
Xencor, Inc.
Phase 1/2
270
London, Montreal, Scarborough, Vancouver
2024-10-10
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic
DrugsEltrekibart·Mirikizumab
Eli Lilly and Company
Phase 2
143
London, Montreal
2024-10-10
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952Prurigo Nodularis
DrugPovorcitinib
Incyte Corporation
Phase 3
349
Calgary, Edmonton, Sherwood Park, Barrie, Cobourg, London, Toronto, Québec
2024-10-10
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Prurigo Nodularis
DrugPovorcitinib
Incyte Corporation
Phase 3
346
Edmonton, Barrie, London, Toronto, Québec, Saskatoon
2024-10-10
Recruiting
Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial
NCT06262048Urinary Retention Postoperative
DrugTamsulosin Hydrochloride
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
60
London
2024-10-01
Not yet open
Feasibility of a Cardiac Rehabilitation Program for CTO Patients Before PCI Treatment
NCT06610708Chronic Total Occlusion (CTO)
Luiz Ybarra
Not applicable
70
London
2024-10
Recruiting
Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy
NCT06634108Amyloid Cardiomyopathy
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1/2
20
London
2024-09-27
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
DrugGSK4532990
GlaxoSmithKline
Phase 2
393
Calgary, New Westminster, Vancouver, London, Toronto, Montreal, Terrebonne
2024-09-27
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
Stemline Therapeutics, Inc.
Phase 3
4,220
Surrey, Vancouver, Barrie, London, Toronto, Montreal, Saint-Charles-Borromée, Saint-Jérôme
2024-09-27
Recruiting
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
NCT06396416Obesity, Chronic Kidney Disease
DrugsOzempic·Wegovy·Semaglutide
Western University, Canada
Phase 4
60
London
2024-09-26
Active, closed
A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
NCT06564636Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis
Smith & Nephew, Inc.
Observational
119
Edmonton, Vancouver, Winnipeg, London
2024-09-26
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
96
Vancouver, London, Toronto
2024-09-25
Active, closed
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794Acute Gastroenteritis, Norovirus Acute Gastroenteritis
DrugMRNA-1403
ModernaTX, Inc.
Phase 3
37,864
Calgary, Chicoutimi, Greater Sudbury, Guelph, Halifax, Kelowna, Lévis, London
2024-09-24
Active, closed
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 1/2
20
Calgary, Vancouver, London
2024-09-18
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Halifax, London, Montreal, Ottawa, Québec, Toronto
2024-09-18
Recruiting
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06081348Neurodevelopmental Disorders, Autism, Autism Spectrum Disorder, Fragile X Syndrome
DrugsZoloft·Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 2
130
Calgary, Edmonton, Halifax, Hamilton, Kingston, London, Toronto
2024-09-16
Recruiting
M3-JIA: Making Mindfulness Matter for Children With JIA
NCT06376149Juvenile Idiopathic Arthritis, Children, Mental Health, Mental Well-being
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
74
Hamilton, London, Toronto
2024-09-12
Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916Melanoma
DrugsFianlimab·Relatlimab·Cemiplimab·Nivolumab
Regeneron Pharmaceuticals
Phase 3
560
Edmonton, London, Toronto, Montreal, Québec
2024-09-09
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
590
Calgary, Edmonton, Greater Sudbury, London, Vaughan, Montreal, Québec
2024-09-04
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
Calgary, London, Ottawa, Toronto
2024-09-03
Active, closed
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
NCT06503731Antibody-mediated Rejection
argenx
Phase 2
33
London
2024-08-30
Recruiting
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals
Phase 1/2
54
Edmonton, London, Toronto, Montreal
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin
Gilead Sciences
Phase 3
640
Calgary, London, Montreal, Québec, Toronto
2024-08-28
Recruiting
A Mobile Recovery Guidance App for Children and Young Adults With Acute Ankle Inversion Injuries
NCT05785533Ankle Sprains
Naveen Poonai
Not applicable
250
London
2024-08-24
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
DrugsRiliprubart·IVIG
Sanofi
Phase 3
160
London, Montreal, Québec
2024-08-21
Recruiting
Breast 3DUS ABUS System Comparison
NCT06118996Breast Diseases
Western University, Canada
Not applicable
30
London
2024-08-18
Recruiting
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
DrugVedolizumab
Alimentiv Inc.
Phase 4
304
Calgary, Edmonton, Bridgewater, London, Toronto
2024-08-07
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
London, Fleurimont, Montreal, Québec
2024-08-05
Active, closed
Long-term Extension of GTX-102 in Angelman Syndrome
NCT06415344Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 3
255
Calgary, Vancouver, London, Ottawa, Montreal
2024-07-31
Recruiting
Hemiarch vs Extended Arch in Type 1 Aortic Dissection
NCT03885635Aortic Dissection
Ottawa Heart Institute Research Corporation
Not applicable
50
London, Toronto, Montreal, Québec
2024-07-30
Active, closed
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816Geographic Atrophy
DrugVonaprument
Annexon, Inc.
Phase 3
659
Calgary, Edmonton, London, Ottawa
2024-07-30
Active, closed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
446
Victoria, Brampton, London, Sarnia, Waterloo, Montreal, Québec, Halifax
2024-07-22
Active, closed
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
NCT06384261Leukemia, Myeloid, Acute
DrugsCusatuzumab·Azacitidine·Venetoclax
OncoVerity, Inc.
Phase 2
140
Calgary, Edmonton, Vancouver, London, Ottawa, Toronto, Saskatoon
2024-07-22
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323Asthma
DrugDepemokimab
GlaxoSmithKline
Phase 3
150
Ajax, Hamilton, London
2024-07-19
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
976
Edmonton, Hamilton, London, North Bay, Ottawa, Richmond Hill, Toronto, Windsor
2024-07-19
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
London, Toronto, Montreal
2024-07-19
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883Inflammatory Bowel Diseases, Crohn's Disease
DrugZotemtegrast
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Alberta, Chicoutimi, Halifax, Lethbridge, London, Montreal, Québec, Scarborough
2024-07-18
Recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580Generalized Myasthenia Gravis
DrugTelitacicept
Vor Biopharma
Phase 3
180
London, Toronto
2024-07-17
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746Heart Failure
DrugsFinerenone·Dapagliflozin
Colorado Prevention Center
Phase 3
1,500
Edmonton, Surrey, Greater Sudbury, London, North York, Toronto, Montreal, Sherbrooke
2024-07-09
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Calgary, Edmonton, Kelowna, Fredericton, St. John's, Cobourg, Hamilton, London
2024-06-27
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485Rectal Cancer
DrugsLeucovorin·Capecitabine·Oxaliplatin
Canadian Cancer Trials Group
Phase 3
250
Vancouver, Winnipeg, St. John's, London, Ottawa, Montreal, Regina, Saskatoon
2024-06-26
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Vancouver, Halifax, London, Toronto, Montreal, Rimouski
2024-06-25
Recruiting
Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
NCT06670638Crohns Disease
Alimentiv Inc.
Observational
50
Hamilton, London
2024-06-19
Recruiting
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
NCT06124976Urothelial Carcinoma of the Renal Pelvis and Ureter, Transitional Cell Cancer of the Renal Pelvis and Ureter
Peter Black
Phase 2/3
70
Vancouver, Winnipeg, Halifax, London, Toronto, Montreal, Sherbrooke
2024-06-19
Recruiting
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128Ulcerative Colitis
DrugsXeljanz·Vedolizumab·Tofacitinib
Takeda
Phase 4
60
Barrie, London, Mississauga, North Bay, North York, Oakville, Oshawa, Vaughan
2024-06-12
Active, closed
Portable Neuromodulation Stimulator (PoNS®) Therapy for Gait and Balance Deficits in Chronic Stroke Survivors: A Randomized Controlled Trial.
NCT06470009Chronic Stroke Survivors
Helius Medical Inc
Not applicable
60
Calgary, London, Verdun
2024-06-12
By invitation
Biomarkers in a Candian Memory Clinic
NCT06843109Alzheimer&#39;s Disease (AD)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
100
London
2024-06-11
Recruiting
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT06410976Hypochondroplasia
QED Therapeutics, a BridgeBio company
Observational
150
London, Ottawa, Montreal
2024-06-05
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
London, Québec
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Calgary, Edmonton, Lethbridge, New Westminster, Vancouver, Kentville, Barrie, London
2024-06-05
Not yet open
Prolonged Hypercoagulability Following Major Liver Resection for Malignancy
NCT06153394Hepatic Disease, Surgery-Complications, Hypercoagulability, Thrombosis
DrugsFragmin·Dalteparin
Western University, Canada
Phase 3
50
London
2024-06-01
Recruiting
Diaphragmatic Inspiratory Amplitude as a Prognosticator for Postoperative Pulmonary Complications After Cardiac Surgery
NCT06396767Postoperative Pulmonary Complications, Cardiac Surgery
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
130
London
2024-06-01
Recruiting
Predicting Psychotic Relapse Using Speech-Based Early Detection
NCT06978894Psychosis
Douglas Mental Health University Institute
Observational
250
London, Montreal, Québec
2024-05-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Calgary, Vancouver, Winnipeg, London, Ottawa, Toronto, Vaughan
2024-05-24
Active, closed
Albumin Utilization in Adult Cardiac Surgical Patients: Retrospective
NCT06322537Cardiovascular Surgical Procedures, Albumin
University Health Network, Toronto
Observational
505
New Westminster, Vancouver, Halifax, Hamilton, Kingston, London, Ottawa, Toronto
2024-05-23
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Calgary, Edmonton, Red Deer, Vancouver, Moncton, St. John's, Hamilton, London
2024-05-20
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Calgary, Edmonton, Red Deer, Kelowna, Surrey, Winnipeg, Ajax, London
2024-05-08
Active, closed
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925Colitis, Ulcerative
DrugEtrasimod
Pfizer
Observational
360
Kelowna, New Westminster, Richmond, Vancouver, London, Ottawa, Montreal
2024-05-08
Recruiting
Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study
NCT06249269Atrial Fibrillation, Paroxysmal or Persistent
Ratika Parkash
Observational
198
Calgary, Halifax, London, Ottawa, Toronto, Montreal, Regina
2024-05-01
Recruiting
iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease
NCT06371937Cardiovascular Diseases, Arrythmia, Cardiomyopathies, Heart Failure
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
200
London
2024-05-01
Recruiting
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
NCT05884723Liver Steatoses, Liver Metastasis Colon Cancer, NAFLD
Anton Skaro
Not applicable
124
London
2024-05-01
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
DrugRetatrutide
Eli Lilly and Company
Phase 3
10,000
Calgary, Chicoutimi, Courtice, Edmonton, London, Moncton, North York, Oshawa
2024-04-30
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
DrugClazakizumab
CSL Behring
Phase 2/3
3,110
Edmonton, Halifax, Hamilton, Kingston, London, Oshawa, Montreal, Longueuil
2024-04-27
Recruiting
Early Severe Illness TrAnslational BioLogy InformaticS in Humans
NCT05591924Sepsis, ARDS, Critical Illness, Neurocognitive Dysfunction
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
1,000
London
2024-04-26
Recruiting
RAFT - Pace &Ablate
NCT06299514Atrial Fibrillation, Heart Failure, Pacemaker, Arrhythmia Atrial
Habib Khan
Not applicable
600
Victoria, Halifax, Hamilton, Kitchener, London, Newmarket, Ottawa, Toronto
2024-04-25
Recruiting
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT06235697Prostate Cancer
Canadian Cancer Trials Group
Phase 3
710
St. John's, Barrie, Kingston, Kitchener, London, Mississauga, Oshawa, Toronto
2024-04-25
Recruiting
Personalized Pharmacotherapy Using Pharmacogenetics in Veterans
NCT06335043Pharmacogenetic Testing to Determine Pharmacological Treatment in PTSD
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
155
London
2024-04-25
Recruiting
Prediction of Intraventricular Hemorrhage Using Echocardiography and Near Infrared Spectroscopy
NCT05708105Intraventricular Hemorrhage of Newborn Grade 2, Intraventricular Hemorrhage of Newborn Grade 3, Intraventricular Haemorrhage Grade IV
Mount Sinai Hospital, Canada
Observational
380
Calgary, Edmonton, London, Toronto
2024-04-22
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296Ganglioneuroblastoma, Nodular, Neuroblastoma
DrugsDinutuximab·Isotretinoin·CDDP·Doxorubicin
National Cancer Institute (NCI)
Phase 3
478
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, London
2024-04-19
Recruiting
Is Radiation-before-pathology a Feasible Approach in the Palliative Oncology Setting? A Pragmatic Clinical Trial
NCT06156800Cancer
David Palma
Observational
48
London
2024-04-19
Recruiting
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754Crohn's Disease
DrugsHumira·Ustekinumab·Vedolizumab·Adalimumab
Takeda
Phase 4
50
Edmonton, London, North Bay, North York, Oakville, Vaughan, Montreal
2024-04-18
Recruiting
Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)
NCT05452356Heart Diseases, Arrhythmias, Cardiac, Atrial Fibrillation, Cardiovascular Diseases
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
2,000
London
2024-04-18
Active, closed
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935Crohn's Disease
DrugsTremfya·Guselkumab
Janssen-Cilag Ltd.
Phase 3
120
Calgary, London, Montreal
2024-04-17
Recruiting
Using ROSA for Challenging The TKA Standard of Care
NCT06267482Knee Osteoarthritis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
90
London
2024-04-16
Recruiting
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
NCT06037811Inflammatory Arthritis, Immune-related Adverse Event
DrugsAdalimumab·Prednisone
Tom Appleton
Phase 2
30
London
2024-04-15
Active, closed
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750Prurigo Nodularis
DrugBarzolvolimab
Celldex Therapeutics
Phase 2
140
Edmonton, Barrie, Etobicoke, Guelph, London, Toronto
2024-04-12
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
New Westminster, North Vancouver, Vancouver, Winnipeg, Sydney, Cambridge, Hamilton, London
2024-04-12
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Datopotamab deruxtecan·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Vancouver, Winnipeg, St. John's, London, Newmarket, Oshawa, Toronto, Lévis
2024-04-11
Recruiting
Confirming Permanent Lack of Blood Flow to the Brain During A-NRP DCC Organ Transplant
NCT05884736Organ Transplant
Western University, Canada
Observational
30
London, Toronto
2024-04-02
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
579
Winnipeg, Brampton, London, Toronto
2024-03-29
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
213
Calgary, New Westminster, London, Montreal
2024-03-29
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
2,554
Edmonton, Vancouver, Winnipeg, Halifax, Sydney, Brampton, Concord, London
2024-03-29
Recruiting
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
DrugTovorafenib
National Cancer Institute (NCI)
Phase 2
48
Edmonton, Vancouver, Halifax, Hamilton, London, Toronto, Montreal, Sherbrooke
2024-03-28
Active, closed
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
NCT06249555Crohn's Disease
DrugsSkyrizi·Tremfya·Mirikizumab·Risankizumab
Alimentiv Inc.
Observational
300
Edmonton, Vancouver, Brampton, London, Mississauga, Oakville, Ottawa, Scarborough Village
2024-03-20
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Calgary, Vancouver, Winnipeg, London, Ottawa, Toronto, Vaughan
2024-03-13
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
120
Halifax, London, Toronto
2024-03-13
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
90
Halifax, London, Toronto, Vancouver
2024-03-13
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
DrugsPiflufolastat·Lu-PSMA
Novartis Pharmaceuticals
Phase 3
450
Calgary, Halifax, London, Ottawa, Toronto, Montreal, Québec
2024-03-12
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
731
Surrey, Winnipeg, London, Markham, Mississauga, Peterborough, Toronto, Windsor
2024-03-09
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461Crohn's Disease
DrugZasocitinib
Takeda
Phase 2
268
Calgary, New Westminster, Halifax, London, Toronto, Montreal
2024-03-05
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Brampton, Chicoutimi, Hamilton, Joliette, London, Longueuil, Moncton, New Westminster
2024-03-05
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib
AstraZeneca
Phase 3
594
Barrie, London, North York, Ottawa, Toronto, Montreal
2024-03-04
Recruiting
An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL
NCT06032208End Stage Renal Disease
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
100
Winnipeg, Halifax, London
2024-03-01
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
DrugsPimecrolimus·Amlitelimab·Tacrolimus
Sanofi
Phase 3
464
Calgary, Edmonton, Burlington, Hamilton, London, Toronto, Regina
2024-02-29
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Calgary, London, Montreal, Ottawa, Toronto
2024-02-27
Active, closed
Loneliness Group Intervention
NCT05619718Loneliness
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
50
London
2024-02-23
Active, closed
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
NCT06282159Myasthenia Gravis, Generalized
DrugClaseprubart
Dianthus Therapeutics
Phase 2
65
London
2024-02-23
Active, closed
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003Duchenne Muscular Dystrophy, Exon 44, DMD
DrugBrogidirsen
NS Pharma, Inc.
Phase 2
20
Calgary, Vancouver, London
2024-02-22
Recruiting
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
NCT05933057Duchenne Muscular Dystrophy
DrugHydroxyurea
Italfarmaco
Phase 3
138
Vancouver, London, Ottawa, Toronto
2024-02-19
Active, closed
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275Crohn's Disease
AbbVie
Observational
1,200
Calgary, Edmonton, New Westminster, Winnipeg, Halifax, Barrie, London, Mississauga
2024-02-19
Recruiting
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
NCT05149768Diffuse Cutaneous Systemic Sclerosis
DrugBrentuximab Vedotin
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2
11
London
2024-02-14
Recruiting
Low-value Care, and Variation in Practice for Children Hospitalized With Bronchiolitis
NCT06506474Bronchiolitis
St. Justine's Hospital
Observational
3,000
Calgary, Edmonton, Vancouver, Halifax, Hamilton, Kingston, London, Oshawa
2024-02-13
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine
Genmab
Phase 3
1,095
London, Ottawa, Lévis, Montreal
2024-02-05
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma
DrugsRelatlimab·Nivolumab
National Cancer Institute (NCI)
Phase 2/3
992
Calgary, Edmonton, Vancouver, Kitchener, London, Ottawa, Toronto, Regina
2024-02-02
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
617
Calgary, Edmonton, Surrey, Winnipeg, Fredericton, Barrie, Hamilton, London
2024-01-30
Active, closed
PeRiopEratiVE SmokiNg CessaTion Trial
NCT05102123Smoking (Tobacco) Addiction, Smoking Cessation
DrugCytisine
Population Health Research Institute
Phase 3
1,720
Hamilton, Kingston, London
2024-01-15
Recruiting
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
DrugsLutetium Lu 177 Dotatate·Lutathera·Sunitinib·Cabozantinib
National Cancer Institute (NCI)
Phase 2
100
Vancouver, Winnipeg, St. John's, London, Ottawa, Toronto
2024-01-12
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Calgary, Winnipeg, London, Toronto, Chicoutimi, Montreal, Rimouski
2024-01-11
Active, closed
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250Pulmonary Hypertension
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
230
Winnipeg, London
2024-01-10
By invitation
5-SENSE Score Validation Study
NCT06138808Epilepsy Intractable
Duke University
Observational
400
Dalhousie, London
2024-01-09
Active, closed
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT05761171Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
DrugsHydrocortisone Sodium Succinate·Fludarabine Phosphate·Revumenib·Calaspargase Pegol
Children's Oncology Group
Phase 2
78
Vancouver, Winnipeg, Halifax, Hamilton, London, Ottawa, Toronto, Montreal
2024-01-08
Recruiting
POHCA Resuscitation: Evaluation of IM Epinephrine
NCT05166343Pediatric Out-of-Hospital Cardiac Arrest
DrugEpinephrine
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2/3
284
London
2024-01-08
Recruiting
Evaluation of the Transitional and Lifelong Care Program
NCT05849285Cerebral Palsy, Spina Bifida, Developmental Disability
Western University, Canada
Observational
410
London
2024-01-03
Recruiting
A Nutrition and Exercise Lifestyle Intervention Program Participant Choice Approach
NCT06187675Lifestyle, Healthy, Pregnancy Related, Adherence, Treatment, Nutrition, Healthy
Western University, Canada
Not applicable
120
London
2024-01-01
Recruiting
Emergency Medicine Pulmonary Embolism Testing Multicentre Study
NCT06320236Pulmonary Embolism, D-dimer, Diagnosis
Dr. Kerstin de Wit
Observational
4,000
Hamilton, Kingston, London, Ottawa
2024-01-01
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Calgary, Burnaby, Vancouver, Moncton, London, Ottawa, Toronto, Gatineau
2023-12-27
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Calgary, Edmonton, Halifax, London
2023-12-20
Recruiting
Anxiolysis for Laceration Repair in Children
NCT05383495Laceration of Skin, Distress, Emotional
DrugsNitrous oxide·Midazolam·Dexmedetomidine
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3
300
London
2023-12-19
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
367
Vancouver, Halifax, London, Toronto, Montreal
2023-12-14
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugVolrustomig
AstraZeneca
Phase 3
1,145
Calgary, Edmonton, Kelowna, Kingston, London, Toronto, Chicoutimi, Montreal
2023-12-14
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Edmonton, St. John's, London, Ottawa, Gatineau, Granby, Lévis, Québec
2023-12-13
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
100
Calgary, Edmonton, Surrey, Fredericton, Ajax, Barrie, London, Newmarket
2023-12-12
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
DrugRisankizumab
AbbVie
Phase 3
110
Calgary, Edmonton, Vancouver, London
2023-12-11
Active, closed
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
NCT06111586Type 1 Diabetes Mellitus
DrugFrexalimab
Sanofi
Phase 2
197
Vancouver, London, Montreal
2023-12-11
Active, closed
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972Ulcerative Colitis
Gilead Sciences
Phase 2
176
London, Toronto, Vaughan
2023-12-05
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043Ulcerative Colitis
DrugRosnilimab
AnaptysBio, Inc.
Phase 2
132
London, Montreal, Calgary
2023-12-04
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Tegafur·Capecitabine
AstraZeneca
Phase 3
760
Vancouver, Halifax, Kingston, London, Ottawa, Toronto, Montreal, Québec
2023-12-04
Recruiting
Studying the Effects of Cannabis on Vasculature
NCT05581368Cardiovascular Diseases, Inflammation, Atherosclerosis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
100
London
2023-12-01
Recruiting
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Children's Oncology Group
Observational
330
London
2023-11-30
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Hamilton Health Sciences Corporation
Not applicable
4,000
Calgary, Vancouver, Winnipeg, Burlington, Cambridge, Hamilton, Kitchener, London
2023-11-30
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445NonSegmental Vitiligo
DrugPovorcitinib
Incyte Corporation
Phase 3
467
Calgary, Surrey, Burlington, London, North YORK, Ottawa, Peterborough, Waterloo
2023-11-29
Active, closed
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073Multifocal Motor Neuropathy
argenx
Observational
413
London, Montreal, Québec, Saskatoon
2023-11-29
Recruiting
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
NCT05417516Breast Neoplasm Female, Radiotherapy, Cosmetic Outcome
Ontario Clinical Oncology Group (OCOG)
Phase 3
910
Calgary, Victoria, Halifax, Barrie, Hamilton, London, Newmarket, Sault Ste. Marie
2023-11-20
Recruiting
The Role of Synovectomy in Pain Reduction Following Total Knee Arthroplasty
NCT05800457Osteoarthritis, Knee
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
300
London
2023-11-20
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Calgary, London, Toronto, Montreal
2023-11-16
Active, closed
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478Chronic Spontaneous Urticaria
DrugsOmalizumab·Remibrutinib
Novartis Pharmaceuticals
Phase 3
470
Edmonton, Hamilton, London, Niagara Falls, Québec, Verdun
2023-11-15
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsDatopotamab deruxtecan·Epirubicin·Xeloda·Olaparib
AstraZeneca
Phase 3
1,902
Calgary, Vancouver, Barrie, London, Oshawa, Toronto, Lévis, Montreal
2023-11-14
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
1,571
Calgary, Edmonton, Vancouver, Winnipeg, Barrie, Greater Sudbury, London, Mississauga
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
London, Waterloo, Greenfield Park, Montreal
2023-11-07
Recruiting
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
NCT05615844Open tíbia Fracture
University of Maryland, Baltimore
Phase 3
312
New Westminster, Vancouver, Hamilton, London, Ottawa
2023-11-05
Active, closed
Minimally Displaced Femoral Neck Fracture Pilot Study
NCT05947058Femoral Neck Fractures
University of Maryland, Baltimore
Not applicable
40
Vancouver, Hamilton, London
2023-11-01
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
1,600
London, Ottawa, Regina
2023-10-26
Recruiting
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
NCT05928039Crohn Disease
DrugAnti-IL12/23
University of Calgary
Phase 4
297
Calgary, Edmonton, Vancouver, Halifax, Brampton, Brantford, Hamilton, London
2023-10-25
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,020
Calgary, Edmonton, Lethbridge, New Westminster, Vancouver, Kentville, Barrie, London
2023-10-25
Active, closed
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684Myelodysplastic Syndromes
DrugsEpoetin Alfa·Reblozyl·Luspatercept
Bristol-Myers Squibb
Phase 3
402
Calgary, Vancouver, London, Toronto
2023-10-24
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936Lymphoma
DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab
Hoffmann-La Roche
Phase 3
182
London, Ottawa, Toronto
2023-10-22
Recruiting
Investigating Genetic Status in Patients Presenting to Clinic
NCT05911932Dementia, Frontotemporal, Alzheimer Dementia (AD), Lewy Body Dementia (LBD)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
1,000
London
2023-10-20
Active, closed
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333Congestive Heart Failure
AskBio Inc
Phase 2
150
Winnipeg, St. John's, London, Toronto, Chicoutimi, Montreal, Québec
2023-10-20
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926Breast Cancer
DrugOvarian Function Suppression
NRG Oncology
Phase 3
3,960
Barrie, Kitchener, London, Oakville, Oshawa, Toronto, Montreal, Québec
2023-10-18
Recruiting
Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial
NCT05508464Metastatic Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
138
London, Montreal
2023-10-16
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
684
Calgary, Edmonton, Surrey, London, Newmarket, Toronto, Windsor, Montreal
2023-10-12
Active, closed
Virtual Physical Activity Seated Exercise - Phase 2
NCT05724823Stroke, Chronic Stroke, Stroke, Ischemic, Stroke Hemorrhagic
University of British Columbia
Not applicable
100
Vancouver, Winnipeg, Halifax, London, Saskatoon
2023-10-11
Recruiting
Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volatile AnEsthestic Agents
NCT05867472Intensive Care Units, Pediatric, Anesthetics, Inhalation, Mechanically Ventilated, Critically Ill Children
DrugIsoflurane Inhalant Product
Sunnybrook Health Sciences Centre
Phase 3
60
Hamilton, London, Toronto
2023-10-10
Recruiting
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
NCT05717166Metastatic Tumor
David Palma
Phase 3
180
Prince George, Vancouver, London, Montreal
2023-10-06
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
106
Etobicoke, London, Toronto, Montreal
2023-10-02
Recruiting
Cannabidiol Medication Intervention Trial
NCT06014424Alzheimer Disease
Sunnybrook Health Sciences Centre
Phase 2
40
Calgary, London, Toronto, Whitby
2023-09-27
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
DrugVolrustomig
AstraZeneca
Phase 3
800
Hamilton, London, Toronto, Montreal, Ste-Foy
2023-09-22
Recruiting
CTSN Embolic Protection Trial
NCT06027788Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease
Icahn School of Medicine at Mount Sinai
Not applicable
842
London, Ottawa, Montreal, Québec
2023-09-18
Recruiting
SW-RCT Implementation of Canadian Syncope Risk Score Based Practice Recommendations
NCT04972071Syncope
Ottawa Hospital Research Institute
Not applicable
14,400
Calgary, Winnipeg, Greater Sudbury, Hawkesbury, London, North Bay, Thunder Bay, Toronto
2023-09-18
Active, closed
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
NCT05714891NSCLC
DrugJDQ443
Canadian Cancer Trials Group
Phase 2
4
Winnipeg, Kingston, London, Ottawa, Toronto, Montreal, Québec
2023-09-15
Recruiting
Predictors of Risk in Left Ventricular Non-Compaction
NCT06024759Left Ventricular Noncompaction
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
500
London
2023-09-01
Active, closed
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma
DrugsCalaspargase Pegol·Oncaspar·PEG-Asparaginase·Pegaspargase
Children's Oncology Group
Phase 3
440
Halifax, London, Toronto
2023-08-24
Active, closed
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304Advanced or Metastatic Solid Tumors
DrugsNaporafenib·Trametinib
Erasca, Inc.
Phase 1
86
Edmonton, Vancouver, London, Toronto
2023-08-17
Recruiting
Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation
NCT05721261Nerve Injury
Epineuron Technologies Inc.
Not applicable
110
Edmonton, Saint John, Hamilton, London, Newmarket, Toronto
2023-08-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Vancouver, Sydney, London, Toronto, Montreal, Québec
2023-08-08
Recruiting
Evaluating a Virtual Stepped Care Portal in Youth Awaiting Tertiary Chronic Pain Care: An Implementation-Effectiveness Hybrid Type III Study
NCT05894772Chronic Pain
The Hospital for Sick Children
Not applicable
93
Halifax, Hamilton, London, Ottawa, Toronto, Montreal, Saskatoon, Calgary
2023-08-05
Active, closed
A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver
NCT05677113Colorectal Cancer, Liver Metastases
Sunnybrook Health Sciences Centre
Phase 2
115
Hamilton, London, Ottawa, Toronto
2023-08-01
Recruiting
The WHERE Study: Waiting for Hip and KneE REplacement
NCT06074900Hip Osteoarthritis, Knee Osteoarthritis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Observational
3,008
London
2023-07-13
Recruiting
Online Prehabilitation for Patients Awaiting Liver Transplantation
NCT05899231Cirrhosis, Liver, Liver Transplant Surgery, Liver Disease
University of Alberta
Not applicable
177
Calgary, Edmonton, Vancouver, London, Toronto, Montreal
2023-07-12
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Vancouver, Brampton, East York, London, Toronto, Greenfield Park, Montreal
2023-07-06
Recruiting
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NCT05592938Breast Cancer, Breast Cancer Recurrent
University Health Network, Toronto
Not applicable
171
Barrie, London, Oshawa, Toronto, Montreal
2023-06-27
Active, closed
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05776472Paroxysmal Nocturnal Hemoglobinuria
DrugPegcetacoplan
Swedish Orphan Biovitrum
Observational
165
London, Toronto, Montreal
2023-06-26
Recruiting
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
NCT05701358Acute Myocardial Infarction, Coronary Artery Disease
Population Health Research Institute
Not applicable
5,100
Montreal, Brampton, Edmonton, Hamilton, Kingston, Kitchener, London, Newmarket
2023-06-22
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Calgary, Edmonton, New Westminster, Vancouver, Winnipeg, Halifax, Hamilton, London
2023-06-22
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Calgary, Edmonton, Red Deer, Surrey, Winnipeg, St. John's, Hamilton, London
2023-06-21
Recruiting
RTMS and Steroid Joint Steroid Injection in Chronic Spinal Pain
NCT05840354Chronic Spinal Pain
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Not applicable
40
London
2023-06-20
Active, closed
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
NCT05768854Osteogenesis Imperfecta
DrugSetrusumab
Ultragenyx Pharmaceutical Inc
Phase 3
69
London, Ottawa
2023-06-14
Recruiting
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
NCT05612347Colorectal Polyp, Colorectal Neoplasms, Colorectal Adenoma, Colorectal Cancer
Dartmouth-Hitchcock Medical Center
Not applicable
8,946
Calgary, Vancouver, Winnipeg, London
2023-06-14
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
DrugsKeytruda·Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3
1,295
Kelowna, Vancouver, Saint John, Cambridge, Kingston, London, Ottawa, Toronto
2023-06-14
Rows per page Showing 1–500 of 871
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-canada/city/london

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 871 of those studies with a site in London.

How many clinical trials are recruiting in London?

428 of the 871 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 75 have not yet opened recruitment, 354 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 871 studies
PhaseStudiesRecruitingShare
Phase 332214037%
Not applicable2059823.5%
Phase 21286514.7%
Observational1247714.2%
Phase 428173.2%
Phase 2/323122.6%
Phase 12072.3%
Phase 1/21792%
Phase EARLY_PHASE1430.5%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's10856
Western University, Canada3919
AstraZeneca3617
Novartis Pharmaceuticals2414
Eli Lilly and Company2315
Canadian Cancer Trials Group199
AbbVie188
National Cancer Institute (NCI)175
Janssen Research & Development, LLC168
Children's Oncology Group146
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.